The European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has published a status report on its activities related to antimicrobials from 2021 to 2025, alongside a strategic overview for the European Medicines Agencies Network Strategy to 2028 (EMANS 2028) Theme 4. The document, adopted by CVMP on 18 June 2026 and released on 10 July 2026, details progress across six aims: supporting authorisation of effective antimicrobial veterinary medicinal products (VMPs) with safe and sustainable use measures; advising on public health risks versus animal health and welfare needs; ensuring ongoing availability and effectiveness of authorised veterinary antimicrobials; encouraging development of antimicrobial VMPs and products that reduce antimicrobial use; promoting responsible use under marketing authorisations and the cascade; and partnering with EU/EEA and international human and animal health organisations to combat antimicrobial resistance (AMR).
The report covers CVMP's work from 2021 to 2025, including opinions on antimicrobial VMPs, risk assessments, and measures to maintain product availability. It also outlines planned activities under EMANS 2028 Theme 4, which focuses on antimicrobials and AMR. The document was discussed by CVMP on 21 May 2026 and formally adopted on 18 June 2026. No prior coverage of this specific report exists in the last 180 days.
The report impacts several stakeholders. Veterinary pharmaceutical companies face continued regulatory expectations for demonstrating safe and sustainable use of antimicrobials, potentially increasing development costs but also fostering innovation in alternatives. Veterinarians and animal health professionals will see reinforced guidance on responsible use and cascade provisions, which may limit prescribing flexibility but support long-term efficacy of antimicrobials. EU and national regulatory authorities gain a framework for coordinated action on AMR, requiring resource allocation for surveillance and enforcement. Livestock producers and animal owners may experience tighter restrictions on antimicrobial access, potentially raising animal health costs but preserving treatment options for the future. The document does not introduce new binding measures but consolidates ongoing efforts and strategic priorities.